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Abstract
Background: AKXD recombinant inbred strains of mice have proven to be very useful in the identification of potential
oncogenes and tumor suppressors involved in the development of lymphoid and myeloid malignancies. In these tumors,
the hematopoietic insertion of an active AKV murine leukemia virus (MuLV) is associated with the onset of disease. Common
sites of retroviral insertion (CIS) identify genes causally associated with the development or initiation of lymphoma.
Methodology: In the present study, we analyzed a previously uncharacterized CIS, Ecotropic Viral Integration Site 32 (Evi32),
which is located on mouse chromosome 1. We analyzed candidate genes in the region to identify those involved in Evi32
mediated oncogenesis.
Results: Here we show that proviral insertion at Evi32 correlates with significant overexpression of a putative transcription
factor, PR-domain containing 14 (Prdm14). Tumors with insertions at Evi32 are consistently lymphoid in nature. Prdm14 is
normally expressed early in embryonic development with the highest expression in undifferentiated embryonic stem (ES)
cells. This study implicates Prdm14 as a proto-oncogene involved in lymphoblastic lymphoma formation.
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Introduction
Retroviral mutagenesis is an invaluable tool for the identifica-
tion of novel genes involved in the development and progression of
cancer in mice. Germ line retroviruses in certain inbred mouse
strains replicate and infect other cells within the hematopoietic
system. Integrated proviruses may alter the expression of nearby
genes, because the long terminal repeat (LTR) elements contain
enhancers and promoters of transcription [1]. If a proviral
integration alters gene expression in such a way that it gives a
growth advantage to host cells, a clonal expansion of those cells
can occur, ultimately leading to tumor formation. Somatic proviral
insertions contained in tumor tissue act as a molecular tag for the
identification of genomic loci containing genes with oncogenic
transformation ability [2]. In this study, several AKXD recombi-
nant inbred mouse strains were examined that harbor endogenous
replication competent proviruses in their germline and have a high
incidence of lymphoma formation [3]. Each AKXD strain has
variable susceptibility to lymphoma formation affecting both cell
type and frequency [4].
Since it is highly unlikely that a proviral integration would occur
in the same region multiple times in the absence of oncogenic
selection, CISs are assembled to eliminate non-pathogenic
insertions. One CIS that was identified in multiple retroviral
insertional mutagenesis cancer screens is Evi32 [3,5,6,7]. In
previous work, Evi32 was believed to affect flanking gene nuclear
receptor coactivator 2/transcription intermediary factor 2
(NCoA2/Tif2) [5,6,7]. Here we show that a putative transcription
factor, Prdm14, is overexpressed in tumors with proviral integra-
tion at Evi32. Prdm14 is normally expressed at low levels in most
control tissues tested but is massively upregulated in all Evi32
tumors. Prdm14 contains a SET domain and six zinc finger
repeats. SET domains are contained in a variety of transcription
factors and have been shown to be responsible for methylation of
histones [8]. Interestingly, a large proportion of genes containing
SET domains have been implicated in leukemia/lymphoma, such
as the mixed-lineage leukemia (Mll) proteins and B Lymphocyte-
induced Maturation Protein 1 (Blimp1) suggesting that this domain
is commonly involved in tumorigenesis [9]. Our research suggests
that Prdm14 is a novel proto-oncogene involved in the formation of
lymphoma in mice.
Results
Evi32
VISA PCR identified two tumors from mice 27-001 and 27-142
(27 indicates AKXD strain 27 followed by the mouse number)
with insertions at Evi32 [3]. Evi32 is located between Tif2 and
Prdm14 on mouse chromosome 1 (Figure 1a). Both insertion sites
are located very close to the start site of Prdm14, 27-001 is 151bp
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located approximately 15 kb from Tif2, and 136 kb from solute
carrier organic anion transporter family member 5A1 (Slco5a1).
The provirus in 27-001 inserted in the same orientation as Prdm14,
and 27-142 inserted in the opposite direction. Southern blot
analysis after KpnI digestion showed that unique tumor specific
bands were present in both Evi32 tumors, indicating the presence
of somatically acquired proviral integrations at the locus
(Figure 1c). The intensity of the rearranged band indicates that
the integrations at Evi32 are monoclonal. Digestion with EcoRV
Figure 1. Evi32 Viral Insertion Sites. 1a) The genomic locus surrounding Evi32 insertions. Locations of proviral insertions were determined by
either VISA PCR or by PCR after identification of Evi32 integrations. Arrows indicate direction of transcription and the orientation of the retroviral
integration. The exact orientation and location of the retroviral integration in animal 18-077 was not determined, but it is contained between the
HindIII and XbaI digestion sites as determined by Southern blot analysis. Table at top right indicates the distance of each retrovirus from the first exon
of Prdm14. 1b) Closeup view of Evi32 integrations. Restriction enzymes indicated were those used in digestion of tumor DNA to show genomic
rearrangements at Evi32. Arrow indicates direction of transcription of Prdm14, and the black boxes show the eight exons of Prdm14. Prdm14 gene
structure is based on VEGA prediction (OTTMUSG00000017097) obtained from the Ensembl database. RT-PCR amplification indicates that the VEGA
prediction is a true Prdm14 transcript. 1c) Southern blots showing retroviral integrations at Evi32. Genomic DNA from indicated tumors was digested
with KpnI. Brain serves as somatic tissue control from same animal to show rearrangement of Evi32 locus within the tumor tissue only. Rearranged
bands seen in Evi32 tumors are indicated by asterisks and show genomic rearrangements at Evi32. BR=Brain, SP=Spleen, LN=Lymph Node.
doi:10.1371/journal.pone.0003823.g001
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ments at Evi32 (data not shown).
To identify additional Evi32 tumors, all of our AKXD tumors
(from 204 animals) were further screened by Southern blotting
using EcoRV digestion. This analysis revealed that tumors from
mice 27-186 and 18-077 (from AKXD strain 18, mouse 77)
contain rearrangements at Evi32 (Figure 1c). Digestion of 18-077
and 27-186 genomic DNA with EcoRI indicates that both of these
proviruses are ecotropic (data not shown). The retroviral insertion
in tumor 27-186 is located approximately 450 bp from the first
exon of Prdm14 between the 27-001 and 27-142 insertions and
integrated in the same orientation as Prdm14 (Figure 1b). The
genomic location of this insertion was determined using PCR
amplification (data not shown). The exact location of the insertion
in the tumors obtained from mouse 18-077 was not determined,
but it is located within the 1.4 kb region (as determined by
Southern blot analysis with HindIII and XbaI) surrounding the first
exon of Prdm14 indicated in Figure 1b. We were unable to amplify
the virus using viral specific primers, which could be due to
retroviral rearrangements that prevented PCR amplification from
the virus. Southern blot analysis after KpnI digestion indicates that
the LTR elements may have been deleted in 18-077, making
precise localization difficult. Analysis of the number of monoclonal
ecotropic somatic retroviral integrations in the tumors indicated a
relatively low number of integrations (Supplementary Figure S1
and Table S1). Southern analysis of tumors obtained from 27-186
and 18-077 indicated just a single retroviral integration event.
Tumors from 27-001 and 27-142 had three and two somatic
insertions respectively.
Tif2 and Slco5a1 are not misexpressed in tumors
containing insertions at Evi32
Quantitative RT-PCR (Q RT-PCR) was used to determine the
level of expression of the genes surrounding Evi32. Since
retroviruses can alter expression of genes up to 200 kb away
[10], we analyzed expression of Slco5a1 in tumors with Evi32
proviral integrations (Figure 2a). We found that Slco5a1 was
expressed in all Evi32 tumors at lower levels than seen in normal
spleen, thymus, and bone marrow. Lower levels of expression of
Slco5a1 were also observed in all tumors that lacked proviral
insertions at Evi32. Therefore, expression of Slco5a1 is not
significantly altered by proviral integration at Evi32.
Q RT-PCR was also used to determine the level of expression of
Tif2 (Figure 2b), which is listed in the Retrovirus Tagged Cancer
Figure 2. Tif2 and Slco5a1 are not misexpressed in Evi32 tumors. 2a) Q RT-PCR was performed on cDNA prepared from total RNA samples from
tumors with and without insertions at Evi32 and control tissue obtained from 8 week old C57BL/6J mice. Expression of Slco5a1 was normalized to 18S
expression levels and then quantified. We found that the expression of Slco5a1 does not appear to be consistently altered with Evi32 proviral
insertions and is expressed at lower levels than seen in normal spleen, thymus, and bone marrow. Expression levels are shown on a log scale to show
lower levels of expression. 2b) Expression of Tif2 was quantified in the same manner as Slco5a1. This analysis revealed that Tif2 is expressed at similar
or lower levels than normal spleen, thymus, or bone marrow in all Evi32 tumors. Expression levels are shown on a log scale to show lower levels of
expression. 2c) Northern blot analysis of Tif2 was performed using total RNA obtained from Evi32 tumor 27-186 and control tissue obtained from 8
week old C57BL/6J mice. The probe to Tif2 was directed towards common exons found in all isoforms. Sizes were estimated using 18S and 26S
migration distances. The 27-186 Evi32 tumor showed the greatest expression of Tif2 as determined by Q RT-PCR, but shows no increase in expression
by northern analysis. SP=Spleen, LN=Lymph Node, Th=Thymus.
doi:10.1371/journal.pone.0003823.g002
Prdm14 in Mouse Lymphoma
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associated with viral insertion in this region (http://rtcgd.abcc.
ncifcrf.gov/). All Evi32 tumors expressed Tif2 at similar or lower
levels than normal hematopoietic tissues (spleen, thymus, and bone
marrow). Additionally, the level of Tif2 expression by northern
blot analysis in tumor 27-186 appeared to be the same as control
spleen (Figure 2c). Therefore, no consistent alteration in the
expression of Tif2 could be correlated with proviral insertion at
Evi32.
TIF2 is capable of inducing acute myeloid leukemia as a gene
fusion product with monocytic leukemia zinc finger (MOZ).
However, expression of unaltered TIF2 alone is unable to induce
leukemia formation [11]. To rule out any rearrangements that
may result in aberrant transcripts of Tif2, we performed northern
blot analysis. Three isoforms of Tif2 are annotated in the Ensembl
database, and a probe consisting of eight common exons was used
to detect Tif2 rearrangements. This analysis revealed no altered
gene products of Tif2 in the Evi32 tumor 27-186 (Figure 2c).
Furthermore, all bands were consistent with previously described
Tif2 transcript sizes [12,13,14]. All other tumors were also
analyzed by northern analysis and no additional transcripts were
revealed (data not shown). Together, these analyses indicate that
the transcription of Tif2 is not altered with proviral integration at
Evi32.
Prdm14 is overexpressed in Evi32 tumors
Prdm14 is encoded by eight exons spanning 13.7 kb on mouse
chromosome 1. The intron-exon structure of the gene is well
conserved with the human homologue PRDM14 on human
chromosome 8. The predicted protein of Prdm14 is that of a
transcription factor, containing six C2H2 type zinc finger domains
and a SET domain. Other proteins containing these domains have
been shown to have a role in transcription, such as Blimp1
(Reviewed in [15]).
Q RT-PCR was performed on the Evi32 tumors using the
VEGA predicted sequence for Prdm14 as a guide. We found that
this transcript was massively upregulated in all tumors containing
Evi32 insertions compared to all Evi32 negative AKXD tumors
and control tissue examined (Figure 3a). Prdm14 was expressed
between 30 and 50 fold more in Evi32 tumors than in control
spleen. Moreover, this overexpression was seen in all Evi32 tumors
and observed only in those tumors with proviral insertions at
Evi32. This shows that overexpression of Prdm14 is limited to
AKXD tumors containing Evi32 proviral integrations.
Northern analysis was then performed to confirm the
overexpression of Prdm14 and determine the size of the Prdm14
transcripts. This analysis showed a high level of expression of
Prdm14 specifically in all Evi32 tumors, but not in any control
RNA tested (Figure 3b). Two major transcripts were observed in
Figure 3. Prdm14 is overexpressed in Evi32 tumors. 3a) Q RT-PCR was performed on cDNA prepared from total RNA samples from AKXD tumors
with and without insertions at Evi32 and control tissue obtained from 8 week old C57BL/6J mice. As before, expression levels were normalized to 18S
expression then quantified. This analysis revealed that Prdm14 expression was upregulated in all Evi32 tumors. The expression levels of Prdm14 in
Evi32 tumors varied between 30 and 50 fold more than in control spleen. 3b) Northern analysis of Prdm14 was performed using total RNA obtained
from Evi32 tumors and control tissue obtained from 8 week old C57BL/6J mice. The probe to Prdm14 was nearly the full length coding sequence
amplified by PCR. Sizes were estimated using 18S and 26S migration distances. This analysis shows specific upregulation of Prdm14 in all Evi32
tumors. 3c) RT-PCR was performed on Evi32 tumors using a viral 39 LTR specific primer coupled with a Prdm14 second exon primer. cDNA obtained
from the 27-001 produced a prominent band consistent with a viral fusion transcript. 3d) The amplicon from 27-001 was sequenced, and viral
elements were found to be linked to the second exon of Prdm14 which contains the beginning of the coding sequence of Prdm14. SP=Spleen,
LN=Lymph Node, Th=Thymus.
doi:10.1371/journal.pone.0003823.g003
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2.7 kb transcript is consistent with the VEGA prediction
OTTMUSG00000017097 of Prdm14 (http://vega.sanger.ac.uk/).
This transcript is also supported by RT-PCR analysis using RNA
obtained from tumor tissue (data not shown). The larger transcript
could be a pre-mRNA of Prdm14 or the result of altered splicing
due to retroviral integration at Evi32. Tumor 27-001 also
appeared to have an additional band, which was slightly larger
than the 6.5 kb band. However, this additional transcript was not
observed in any of the other tumors.
To determine whether transcription of Prdm14 was being driven
directly from the proviral LTR elements, we performed RT-PCR
using viral 39 LTR specific primers [16]. A primer specific to the
second exon of Prdm14 (first coding exon) was used as the reverse
primer. All Evi32 tumors were analyzed; however, only 27-001
produced a PCR product (Figure 3c). The amplicon was
sequenced and showed a fusion between the second exon of
Prdm14 and the 39 LTR of the provirus (Figure 3d). This viral
fusion transcript could be the additional larger transcript seen in
the northern analysis of 27-001 in Figure 3c. The presence of this
additional message suggests that transcription of Prdm14 is being
driven from the 39 LTR of the provirus and splicing into Prdm14,
further suggesting that Prdm14 is being altered specifically by
proviral integrations at Evi32.
Normal expression of Prdm14
Since very little is known about Prdm14, we sought to determine
its normal expression pattern. Compared to Evi32 tumors, we
found very low levels of expression of Prdm14 in all normal adult
tissues as determined by Q RT-PCR (Figure 3a, 3b). We next
examined expression of Prdm14 during embryonic development.
The highest embryonic levels of expression were found in
undifferentiated embryonic stem cells in culture (AB2.2 and Rosa
26 reporter ES cells) (Figure 4b). All other embryonic time points
tested showed relatively low levels of Prdm14; however, amongst
these, the earlier embryonic stages (starting at E6.5) show higher
levels of expression of Prdm14 than do later developmental time
points (up to E16.5). The 2.7 kb transcript is present in ES cells,
but the 6.5 kb band is absent (Figure 4a). To confirm that the ES
cells were in an undifferentiated state, Oct-3/4 was used as a
marker of pluripotency [17]. We found high levels of Oct-3/4
expression in the ES cells, with low expression levels in all other
embryonic tissues tested (Figure 4c). This analysis also revealed
that Oct-3/4 is expressed at relatively high levels in Evi32 tumors,
which was striking because we found no expression of Oct-3/4 in
control bone marrow and spleen. We examined AKXD tumors
without proviral insertions at Evi32 from the AKXD-27 and -18
strains, in which all Evi32 insertions occurred, as well as from the
AKXD-9, -10, -13, and -16 strains, which did not have any Evi32
insertions, for Oct-3/4 expression. Although some strains appeared
to have lower expression, there was not significantly more Oct3/4
expression in Evi32 tumors compared with those lacking Evi32
integrations (p=0.53 by the student’s t-test) (Supplementary
Figure S2).
Analysis of Evi32 tumors
Evi32 tumors were originally typed by histopathology and B-
and T-cell receptor rearrangements, and were classified as
lymphoblastic lymphomas (Supplementary Table S1). Altogether,
insertions at Evi32 occurred in 2.0% of the 204 AKXD tumors
acquired in this study. However, within AKXD strains 18 and 27,
Evi32 integrations occurred in 2.4% (1 of 42 tumors) and 7.3% (3
of 41 tumors) of all tumors, respectively. All three tumors from
AKXD strain 27 (27-001, 27-142, and 27-186) were classified as
mixed B/T cell by Southern analysis. In total, Evi32 insertions
occurred in 13% (3 of 23 total) of the mixed B/T lineage tumors
and in 43% (3 of 7 tumors) of the mixed B/T tumors from
AKXD-27. The fourth tumor (18-077) was classified as a T-Cell
lymphoblastic lymphoma in AKXD strain 18. No Evi32 insertions
were identified in 121 tumors from seven other AKXD lines (2, 3,
9, 10, 13, 14, and 16). However, Evi32 retroviral integrations were
found in six additional tumors in the Mouse RTCGD. Four of
these tumors were classified as B-cell, one was a mixed B-/T-cell,
and the last was a myeloid tumor on the BXH2-Runx1+/2
background).
Discussion
In this work, we have demonstrated that Evi32 is a CIS in
AKXD mice. All insertions were clustered very tightly at the start
of the SET domain-containing gene, Prdm14. Previously, it was
thought that insertions at this CIS would affect Tif2, since human
TIF2 acts as a fusion oncogene with MOZ [18,19]. When this
fusion oncogene is overexpressed in mice via retroviral transduc-
tion, the mice consistently develop acute myeloid leukemia [11],
whereas tumors with insertions at Evi32 are lymphoblastic
lymphomas. Furthermore, we have found that Tif2 transcripts
are not altered in tumors with insertions at Evi32. Instead, each of
the tumors with insertions at Evi32 expresses Tif2 at a level that is
similar to or lower than normal hematopoietic organs. However,
in all Evi32 tumors, Prdm14 is highly overexpressed. Furthermore,
in one Evi32 tumor, expression of Prdm14 is driven from the LTR
elements of the integrated provirus. Proviral-gene fusions have
been observed at other oncogenes, which are activated by the
insertion, including Evi3 [16]. The chance that a retrovirus would
integrate in such a manner as to allow expression of Prdm14
directly from the LTR elements is unlikely without this event
contributing to tumor formation. Therefore, we propose that
retroviral integration at Evi32 leads to a massive overexpression of
Prdm14 contributing to lymphoma in these mice.
There is substantial evidence that PRDM14 is involved in
human cancer as well. In a screen for differentially methylated loci
in human breast cancer epithelial cells, the second intron of
PRDM14 had increased levels of DNA methylation [20]. Higher
levels of PRDM14 expression correlated with the increased
methylation state in those breast cancer cells [20]. Furthermore,
PRDM14 is overexpressed in 57–75% of breast cancers examined
and is correlated with genomic amplification at its locus indicating
a causative role [21]. Our research indicates that Prdm14 may also
be involved in murine leukemia/lymphoma development.
Another PR-domain containing gene, PRDM16, has also been
implicated in t(1;3)(p36;q21) and t(1;21)(p36;q22) acute myeloid
leukemias [22,23,24,25]. In these cases, the short form lacking the
PR-domain, MEL1S/sPRDM16, is often overexpressed [26,27].
Additionally, retroviral integrations in Prdm16 in mouse hemato-
poietic cells has been associated with myeloid leukemia, as well as
the immortalization of progenitor cells [28,29]. A recent paper
implies that the oncogenic potential of PRDM16 lies in
sPRDM16, which lacks the PR-domain [30]. However, for
Prdm14, we observed high expression of a PR-domain containing
transcript in all Evi32 lymphomas. This could indicate that among
PRDM family members, the lack of the PR-domain is not always
required for transformation.
Within our screen, all tumors with insertions at Evi32 occurred
in mice from only two AKXD lines of nine total strains aged [3].
Furthermore, three of four of the Evi32 tumors were identified
from AKXD strain 27. This is probably due to strain specific
genetic background differences in strain 27 that predispose mice to
Prdm14 in Mouse Lymphoma
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AKXD-27 may cooperate with Prdm14. Identifying these cooper-
ating genes may uncover mechanisms by which Evi32 tumorigen-
esis occurs. This illustrates the importance of using multiple
genetic backgrounds in retroviral mutagenesis screens. If AKXD-
27 had not been included, Evi32 would not have been identified as
a common insertion site in our study. However, it was identified in
other screens and in a recent screen in a Bloom Syndrome
deficient genetic background [3,5,6,7]. Such information suggests
that Prdm14 may predispose to leukemia development only under
certain genetic conditions.
Very recently, mice deficient for Prdm14 were generated [31].
While the mice appeared normal; they had impaired fertility. The
Prdm14
2/2 mice failed to develop embryonic germ cells due to a
defect in establishment of a pluripotent state and a failure to reset
the epigenetic programming in primordial germ cells. These two
events are necessary for the formation of embryonic germ cells.
Interestingly, expression of the pluripotency marker Oct-3/4 was
observed in all AKXD tumors examined here, allowing for the
possibility that pluripotency may play a role in tumor susceptibility
when Prdm14 is overexpressed. Together, these observations
suggest that the function of Prdm14 in tumor development may be
promoted in cells with a less differentiated phenotype. It has also
been shown that the ES cell pluripotency markers OCT4, SOX2,
and NANOG bind the promoter of PRDM14 in human ES cells
[32]. si-RNA knockdown of any of these three genes results in a
reduction of PRDM14 in human embryonic carcinoma cells [33].
This implies that Prdm14 may be very important in the
maintenance of an undifferentiated state since the three major
ES cell genes appear to regulate Prdm14 expression in some
manner. Unfortunately, the transcriptional targets of Prdm14
remain to be determined; finding these may further elucidate the
direct role of Prdm14 in cancer development.
This work shows that despite advances in transposable element
mutagenesis [34,35]; retroviral mutagenesis screens still represent
a valuable resource for the identification of novel proto-oncogenes
involved in leukemogenesis. It also highlights the importance of
studying low insertion frequency CISs. Despite Evi32 being
identified as a CIS in other work, Prdm14 went unnoticed, likely
because of the low numbers of tumors with insertions at this locus.
Examination of other genes at CISs that have not been studied
could reveal other novel cancer genes relevant to human cancer.
Further work on Prdm14 will provide a greater knowledge of the
role of SET domain genes in cancer development, as well as a
direct link between tumorigenesis and ES cell biology.
Materials and Methods
AKXD Tumor Screen and VISA PCR
All experiments involving mice were carried out under the
approval of the Institutional Animal Care and Use Committee at
Baylor College of Medicine (BCM). Mice are housed in the
Transgenic Mouse Facility at BCM, under the care of the Center
for Comparative Medicine, which is accredited by the Association
for Assessment and Accreditation of Laboratory Animal Care
International.
Two hundred and four animals from AKXD mouse strains 2, 3,
9, 10, 13, 14, 16, 18, and 27 developed leukemia or lymphoma.
Tumors were named first by AKXD strain followed by the animal
number, and were classified by histopathology and molecular
analysis of B and T-cell rearrangements as previously described
[3]. VISA (Viral Insertion Site Amplification) PCR was performed
on tumor DNA to identify flanking genomic DNA regions as
previously described [3,36]. BLAST analysis of viral sequence tags
(VSTs) was performed to align proviral integrations with the
mouse genome. CISs were assembled when multiple VSTs hit a
region of less than 25 kb. Tumor information can be found on
www.mouse-genome.bcm.tmc.edu/VISION.
Southern blot analysis of Evi32 tumors
DNA was digested with EcoRV, KpnI, and XbaI. The locations of
restriction enzyme sites at the Evi32 locus based on the published
C57BL/6J mouse genome sequence are shown in Figure 1b. A
500 bp probe for Evi32 was produced by PCR amplification.
Location of the probe is indicated in Figure 1b. Primer sets to
generate the probe were: Evi32SPF (59-AGAGCCCTGGATCTC-
TAGCC-39) and Evi32SPR (59-GAGAAAGGGGCGTT-
TAATCC-39). The probe to detect retroviral rearrangements was
based on pEco, which is directed towards the AKV env gene, and is
specific for ecotropic proviruses [37]. The probe was amplified from
AKXD tissue with pEcoSPF (59-CATGCACACAATGGAG-
GATT-39) and pEcoSPR (59-GTCTGACAAGACGGGGTTTG-
39). Southern blotting was performed as previously described [38].
Quantitative RT-PCR (Q RT-PCR)
RNA was produced from snap frozen AKXD tumors and
control C57BL/6 tissue using RNA STAT60 (Tel-Test Inc,
Friendswood Texas) and extracted by company protocol. cDNA
samples were produced from RNA using Multiscribe reverse
transcriptase (ABI Systems, Foster City California) with random
hexamers. Control tissue was obtained from C57BL/6J mice.
Embryonic tissue was obtained after (FVB/N X 129S6/SvEv)F1
female mice were mated with FVB/N male mice and monitored
for vaginal plug formation, and then sacrificed at specified
embryonic days. Whole embryos were used for RNA preparation.
RNA was obtained from ES cell lines AB2.2 and Rosa 26 (R26R),
cultured on SNLP 76/7-4 Puro feeder cells. RNA from the feeder
cells was also prepared.
Q RT-PCR was performed using the ABI Prism 7000 Sequence
Detection System. Primers were designed across exon junctions
using Primer Express 3.0 (ABI Systems, Foster City California).
Primers to Tif2 were Tif2RTF (59-AAGTTCTGAGAC-
gAAGGGTTGGC-39) and Tif2RTR (59-GCCATCAGACAAA-
GAAAAACGATAG-39), for Slco5a1 were Slco5a1RTF (59-
ATCCCTTACACAACGGGACCT-39) and Slco5a1RTR (59-
CCTGTCAGATTCCTATGAGGCAT-39). Primers for Prdm14
were Prdm14RTF (59-CGGAAGGTCTCTGCCTCATG-39) and
Prdm14RTR (59-CAAAGTGTGGCACATCACCAA-39). Prim-
ers for Oct-3/4 were Oct3/4F (59-GCCAATCAGCTTGGGC-
TAGA-39) and Oct3/4R (59-TGGCGCCGGTTACAGAA-39).
18S amplification was used to normalize the level of cDNA in each
samples using primers 18SRTF (59-GTAACCCGTTGAACCC-
Figure 4. Prdm14 is expressed most highly in ES cells. 4a) Northern analysis of embryonic tissue compared with the Evi32 tumor 27-186. Gapdh
was used as a loading/RNA integrity control. We found expression of the 2.7 kb band in all ES cell samples, but none in any of the other embryonic
tissues. The larger 6.5 kb transcript seen in the Evi32 tumor is not found in the ES cells. 4b and c) Quantitative RT-PCR was performed on cDNA
obtained from the same tissue from 4a. Prdm14 and Oct-3/4 expression levels were quantified relative to 18S expression levels within each tissue.
Expression levels are on a log scale to emphasize lower levels of expression. Results show specific expression of Prdm14 within Oct-3/4 positive ES-
cells. All embryonic days are whole embryos unless otherwise indicated. YS=yolk sac.
doi:10.1371/journal.pone.0003823.g004
Prdm14 in Mouse Lymphoma
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39). All primer sets were optimized by running pairwise
combinations of 50 nM, 300 nM, and 900 nM concentrations of
forward and reverse primers. SYBR Green 2x master mix (ABI
Systems, Foster City California) was used in all reactions. Forty
cycles of PCR were used in each Q RT-PCR reaction with a
dissociation step to confirm products. All samples were run in
triplicate, and error bars represent the standard error of the mean.
The relative fold change of gene expression between control and
tumor tissue was calculated using the standard 2
2DDCt method.
Northern blot analysis
Total RNA was prepared from snap frozen tissue using RNA-
STAT60 (Tel-Test Inc). 10 ug of RNA was electrophoresed on a
1% agarose gel using Northernmax 10x gel denaturing solution
(Ambion, Austin TX) in 1x MOPS. Gel was transferred to
Hybond N+ membrane (Amersham Biosciences, Piscataway NJ)
using an alkaline transfer buffer (3M NaCl, 0.01M NaOH).
Membrane was then analyzed using an UltraHyb (Ambion, Austin
TX) solution containing 1610
6 cpm/ml [a-
32P]dATP labeled
probe , which was a near full-length coding cDNA of Prdm14
produced by amplification of reverse transcribed cDNA from
AKXD tumor 27-001 using primers Prdm14FLF (59-ATGGCCT-
TACCGCCCTC-39) and Prdm14FLR (59-TTTATGAAGCCT-
CATGTGGGCAT-39). BLAST analysis of the 1677 bp Prdm14
northern probe against murine cDNA reveals limited homology
with other genes. The highest conservation is with EN-
SMUST00000110739 (zinc finger protein 12) with 100% identity
across 24 bp, and the next highest is 87% identity with 40 bp of
ENSMUST00000108985 (A2BE20_MOUSE). Tif2 transcripts
were analyzed using a probe to eight common exons found in
all Tif2 transcript isoforms, which was PCR amplified using primer
sets Tif2NPF (59-CAGTCCAAGGAGGCATGATT-39) and
Tif2NPR (59-GCTCATCTGGCCTGTCATCT-39). RNA sizes
were estimated based on 26S and 18S migration.
RT-PCR analysis of viral fusions
RNA samples were prepared in the same fashion as for Q RT-
PCR analysis. cDNA was produced using Superscript III reverse
transcriptase (Invitrogen, Carlsbad CA) using oligo(dT) primers.
Detection of viral fusion transcripts was performed using primers
specific to a unique portion of the 39 LTR of AKV (59-
CGTGGTCTCGCTGATCCT-39), and to the second exon of
Prdm14 (59-ATCGTGGTACTTCGGGAGTG-39) [16]. After 30
cycles of PCR, the reactions were electrophoresed on a 1%
agarose gel. Positive bands were cut out and sequenced.
Supporting Information
Figure S1 Somatic Ecotropic Viral Integrations in Evi32 tumors.
Southern blot analysis was performed on all tumors containing
Evi32 integrations using SacI and PvuII digestion. Probe to detect
retroviral insertions is directed towards the AKV env gene.
Asterisks indicate rearranged bands within the Evi32 positive
tumors. Differences in unrearranged band pattern between the
AKXD strain 27 and 18 mice indicate the differences in copy
number of AKV between the strains. Total numbers of retroviral
integrations are tabulated in Supplementary Table S1.
Found at: doi:10.1371/journal.pone.0003823.s001 (5.26 MB TIF)
Figure S2 Oct-3/4 expression in AKXD tumors. Quantitative
RT-PCR was performed on AKXD tumor cDNA with or without
Evi32 insertions. First four bars from left represent Evi32 positive
tumors (27-001, 27-142, 27-186, and 18-077); all others were
tested for Evi32 rearrangements by Southern blot analysis and
were negative for Evi32 rearrangements. AB2.2 cDNA serves as a
positive control for Oct-3/4 expression. Figure shows expression of
Oct-3/4 in the majority of AKXD tumors from all lines tested.
Found at: doi:10.1371/journal.pone.0003823.s002 (0.26 MB TIF)
Table S1 Summary of tumor data in Evi32 tumors. Table
summarizes the types of rearrangements observed in the B- and T-
cell receptor in the Evi32 tumors, the pathology of the tumors, the
total number of insertions identified using VISA and via Southern
blotting, and lastly other common sites identified through
sequencing of VSTs. *(27–186 was classified as an enlarged
marginal zone, not neoplastic; however, injection of cells obtained
from this tumor were able to reconstitute in NOD/SCID mice
indicating neoplastic features.)
Found at: doi:10.1371/journal.pone.0003823.s003 (0.03 MB
DOC)
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